glp-1 stomach issues drugs increase risk of acid reflux, GERD, study finds Severe Stomach Paralysis Linked to

Description

Reduces appetite aids weight loss Common Drugs (Examples) Exenatide Liraglutide Dulaglutide Semaglutide Lixisenatide Clinical Uses Type 2 Diabetes Mellitus (as monotherapy or combination) Obesity / weight management (especially semaglutide, liraglutide) Cardiovascular benefit: reduces major adverse CV events in T2DM with CVD Administration Subcutaneous injection (daily or weekly depending on formulation) Oral semaglutide available for some patients Adverse Effects Gastrointestinal: nausea, vomiting, diarrhea Risk of pancreatitis (rare but serious) Mild hypoglycemia if combined with sulfonylureas or insulin Injection site reactions Contraindications / Precautions Personal/family history of medullary thyroid carcinoma History of multiple endocrine neoplasia syndrome type 2 (MEN2) Severe gastrointestinal disease (gastroparesis) GLP-1 agonists = incretin mimetics

Upadacitinib for Acute Severe Ulcerative Colitis

[9] Jayedi, A., Rashidy-Pour, A., Soltani, S., Zargar, M

12 Despite these methodological concerns, warnings about negative retinopathy outcomes are listed in the package inserts of the GLP-1/GIP agonists

Both Toujeo and Lantus are long-acting insulins that contain glargine, however Toujeo is more concentrated containing 300 units per mL of glargine, compared to Lantuss 100 units per mL